IdorsiaXSWX:IDIA +3.67%48 Receivables Turnover is 1.22 as of Mar. 2026. GuruFocus rates XSWX:IDIA with a GF Score™ of 48/100 and a GF Value™ of CHF2.87 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 839 Biotechnology companies, Idorsia ranks better than 52.92% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Idorsia's Revenue for the
three
months ended in Mar. 2026 was CHF57.4 Mil. Idorsia's average Accounts Receivable for the
three
months ended in Mar. 2026 was CHF47.0 Mil.
Hence, Idorsia's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.22.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Idorsia Receivables Turnover Related Terms
Idorsia Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Idorsia's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:IDIA vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Idorsia's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Idorsia Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Idorsia's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Idorsia's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Idorsia (XSWX:IDIA) has a Receivables Turnover of 1.22 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Idorsia and its competitors. According to the industry distribution chart, Idorsia ranks #395 out of 839 companies in the Biotechnology industry, placing it in the top 47.1%.
Is Idorsia's Receivables Turnover too high?
Idorsia's current Receivables Turnover is 1.22. The Biotechnology industry median Receivables Turnover is 5.27. Idorsia's value of 1.22 is 76.9% below this industry median. Based on the distribution chart, Idorsia ranks #395 out of 839 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Idorsia has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Idorsia ranks #395 out of 839 companies for Receivables Turnover. This puts Idorsia in the upper half of its industry. The industry median Receivables Turnover is 5.27. Idorsia's value of 1.22 is 76.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Idorsia's current Receivables Turnover of 1.22 is 76.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Idorsia and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Idorsia's current Receivables Turnover is 1.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (XSWX:IDIA) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.87, compared to a current price of CHF6.63 — trading 131% above its estimated fair value. The current Receivables Turnover is 1.22 and 76.9% below the Biotechnology industry median of 5.27. Idorsia's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Idorsia (XSWX:IDIA), the current Receivables Turnover is 1.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Idorsia (XSWX:IDIA) Overvalued in 2026?
Based on GuruFocus' analysis, Idorsia stock appears to be overvalued.
The current stock price of CHF6.63 is trading 131% above its estimated GF Value™ of CHF2.87.
GuruFocus considers Idorsia to be Significantly Overvalued.
Key valuation signals for XSWX:IDIA:
Receivables Turnover: 1.22
GF Value™: CHF2.87 vs. price of CHF6.63 (131% above fair value)
Industry Position: 76.9% below the Biotechnology median (#395 of 839)
No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
48GF Score
Get the complete analysis for XSWX:IDIA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:IDIA has been successfully added to your 
